LAV

Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China’s first hemophilia B gene therapy, was officially approved

April 11, 2025

Shanghai, China, April 10, 2025 – Belief BioMed ("BBM") and Takeda China today jointly announced...

Syneron Bio Announces Strategic Collaboration with AstraZeneca

March 21, 2025

BEIJING, March 21, 2025 /PRNewswire/ -- Syneron Bio, a cutting-edge oral macrocyclic peptide drug...

Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer

January 17, 2025

SHANGHAI, January 16th, 2025 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company...

Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery

January 13, 2025

[January 13, 2025] – Cornerstone Robotics (the “Company”), a leading global innovator in surgical...

Alebund Pharmaceutical announced the first closing of RMB 550 million in Series C financing

January 7, 2025

January 7, 2025, Alebund Pharmaceuticals (“Alebund” or the “Company”), an integrated...

FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

December 18, 2024

MIAMI--(BUSINESS WIRE)--Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today...

AGAMREE® for DMD Treatment was Approved by China’s NMPA

December 11, 2024

December 11, 2024, Sperogenix Therapeutics announced that, AGAMREE® (vamorolone) was approved by...

Duality Biologics and GSK Enter into Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324)

December 4, 2024

PRINCETON, N.J., SHANGHAI and SUZHOU, China, Dec. 3, 2024 /PRNewswire/ -- Duality Biologics (...

IMPACT Announces Completion of RMB 250 million Sr. D++ Financing

November 15, 2024

SHANGHAI, November 15th, 2024 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company...

GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline

October 29, 2024

CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B...

Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer

September 30, 2024

Cambridge, Massachusetts, September 30, 2024 - Regor Pharmaceuticals (USA) ("Regor") has entered...

ImmuneOnco and Instil Bio Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

August 2, 2024

Shanghai, China and Dallas, TX, August 01, 2024 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ...

Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms

July 19, 2024

- Financing led by LongRiver Investments with participation by new and existing global...

AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease

June 13, 2024

- Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the...

Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment

May 16, 2024

Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to...

The Phase 3 clinical trial data of Senaparib published in Nature Medicine, positioning it as a promising first-line maintenance treatment option for the all-comer population in advanced ovarian cancer

May 15, 2024

On May 15, 2024, the internationally renowned medical journal Nature Medicine (Latest impact...

Impact Raises RMB 400 million in Series D+ Funding

April 19, 2024

SHANGHAI, April 19th, 2024 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company...

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

April 4, 2024

Genmab to acquire ProfoundBio for USD 1.8 billion in cashAcquisition will give Genmab...

NDA of AGAMREE was Accepted and Granted Priority Review by China’s CDE

March 26, 2024

March 26, 2024, the NDA filling of AGAMREE (vamorolone) is indicated for the treatment of...

Scivita Medical Expands Collaboration with Boston Scientific